ARS Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
ARS Pharmaceuticals, Inc. (SPRY)
Company Research
Source: Yahoo! Finance
treated with a single dose—and ARS reported $72.2M U.S. net product revenue and $84.3M total revenue in 2025, its first full commercial year. Growth is constrained by structural market dynamics—refill-dominant prescribing, e-prescribing workflows and payer friction—ARS ended 2025 with ~ 93% commercial coverage but only ~ without prior authorization and ~55% approval when prior authorization is required; management expects meaningful coverage expansion into the summer (CVS formulary changes typically July 1). To accelerate uptake ARS will expand its field team from 106 to 150 , scale the digital “Get neffy on Us” program (˜10% of scripts today) and maintain ~ $100M in DTC/HCP spend, supported by a $245M year-end cash balance while advancing a CSU program with Phase 2b interim data expected H2 2026 and Phase 3 targeted mid-2027. Interested in ARS Pharmaceuticals, Inc.? Here are five stocks we like better. ARS Pharmaceuticals (NASDAQ:SPRY) executives used the company's fourth-qua
Show less
Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRY alerts
High impacting ARS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SPRY
News
- ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines [Seeking Alpha]Seeking Alpha
- ARS Pharmaceuticals (SPRY) was given a new $26.00 price target by Leerink Partners.MarketBeat
- ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Highlights: Strong Market Entry and ... [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization [Yahoo! Finance]Yahoo! Finance
SPRY
Earnings
- 3/9/26 - In-Line
SPRY
Sec Filings
- 3/9/26 - Form S-8
- 3/9/26 - Form 10-K
- 3/9/26 - Form 8-K
- SPRY's page on the SEC website